Pharmaceutical equipment is the upstream of the pharmaceutical industry and plays an important role
in the pharmaceutical production process.
In recent years, with the rapid development of China's biopharmaceutical industry, the pharmaceutical equipment industry has also ushered in good development opportunities, and relevant departments have also paid more attention
to the industry.
The industry believes that at present, driven by policy efforts and market demand, the pharmaceutical equipment industry is expected to usher in a critical period of development, and the pace of domestic substitution is expected to further accelerate
.
Pharmaceutical equipment industry (Image source: Pharma.
com)
Policy assistance
The pharmaceutical industry is an important foundation for the construction of a healthy China, which is related to the national economy and people's livelihood, economic development and national security
.
In recent years, with the aging of the population and the continuous upgrading of consumption, the pharmaceutical industry has ushered in rapid development
.
However, it should also be noted that the matching degree between traditional pharmaceutical equipment and the modernization of the pharmaceutical industry is not high enough, and the quality and safety of drugs are also more prominent
.
In recent years, with the development of a new generation of information technology, a series of policies have been introduced at the domestic and local levels to actively promote the transformation and upgrading
of the pharmaceutical equipment industry.
Previously, the "Guiding Ideology" of the "14th Five-Year Plan" for the development of the pharmaceutical industry pointed out that the modernization level of the pharmaceutical industry chain should be comprehensively improved, the supply chain should be stable and controllable, and the innovation-driven development and transformation
should be accelerated.
This is also regarded by the industry as a signal
that the transformation and upgrading of the pharmaceutical equipment industry will accelerate.
In November 2021, the National Development and Reform Commission and other departments jointly issued the Notice on the Implementation Plan for Promoting the High-quality Development of the API Industry, proposing to support the improvement
of domestic production capabilities of synthetic processes, high-end equipment, high-performance consumables and digitalization technologies involved in API production.
In September 2021, China's four departments jointly issued the "Guiding Opinions on Expanding Investment in Strategic Emerging Industries to Cultivate and Grow New Growth Points", which mentioned that it is necessary to focus on supporting the production of high-end equipment such as pharmaceutical equipment, and implement pilot demonstrations
of intelligent manufacturing and intelligent construction.
The "14th Five-Year Plan for the Development of Shanghai's High-end Equipment Industry" issued by Shanghai proposes that by 2025, it will initially build a high-end equipment innovation growth pole and core technology source with
global influence.
Lianyungang City has also recently released relevant documents, in which it is clear that the municipal development zone will focus on the development of new pharmaceutical industry, new material industry, equipment manufacturing industry, and new business forms
of service industry.
For the new pharmaceutical industry, it is required to develop and expand the high-end chemical drugs, biological drugs, modern traditional Chinese medicine, and high-end medical device industries
.
Demand-driven
Biomedicine is the pillar industry for the development of bioeconomy, in recent years, by the multiple resonance of policies, capital, talents and so on, China's biopharmaceutical industry has ushered in a period of vigorous development, new technologies in the field of biopharmaceuticals have emerged one after another, and the demand for the upstream supply chain market has increased significantly, bringing huge market space
to biopharmaceutical equipment and consumables.
At the same time, due to the impact of the epidemic, the delivery time of imported equipment has been delayed, and domestic equipment enterprises with good performance and service quality have obtained a large number of orders, and their performance has also increased significantly
.
In the post-epidemic era, as the number of domestic biologics approved continues to increase, the industry believes that the demand for the upstream supply chain will continue to expand, and the market scale will continue to expand
.
According to Meticulous Research, the global biopharmaceutical process equipment and consumables market is growing rapidly, with a market size of $11.
2 billion in 2018 and is expected to increase to $22.
3 billion
by 2023.
At present, in order to seize the development opportunities of the biomedical industry and become bigger and stronger, many domestic pharmaceutical machinery companies have actively deployed the biomedical track, and new actions are frequent
.
For example, on September 26, Dongfulong announced that it would "join hands" with Tianjin JEC, and the two sides will reach cooperation
in many fields such as upstream and downstream processes of biopharmaceuticals, GMP production line equipment, core consumables, plant construction, and future factory digitalization and automation.
It is reported that Dongfulong started with freeze-drying, in recent years, the company has comprehensively laid out the upstream and downstream fields of biopharmaceuticals, and the process has always run through the whole process, providing process research, core equipment, consumables, and system engineering overall solutions
.
Chutian Technology also actively exerts efforts in the biomedical track, the company focuses on the middle section of the product sterile preparation sub-packaging related equipment, and has introduced Chutianyuan Chuang, Chutiansi Ute, Chutian Microsphere, Chutiansi Weikang and other cutting-edge biomedical and life science technology companies, as well as Chutian Huaxing, Pilian Chutian and other precision processing supply chain enterprises, its layout of the front, middle and back end equipment can be used in the biomedical track
.
epilogue
At present, the overall localization rate of the biopharmaceutical equipment industry is still relatively low, which means that high-end products have a large space for substitution, and the industry has broad
development prospects.
However, it is also necessary to see that the threshold of some high-end products and technologies is very high, and domestic enterprises need to make a lot of efforts to close the gap with the import level
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
